用于研究脂质纳米颗粒-siRNA 递送达有效率的生理障碍的技术。
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.
机构信息
Department of RNA Therapeutics, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, USA.
出版信息
J Histochem Cytochem. 2013 Jun;61(6):407-20. doi: 10.1369/0022155413484152. Epub 2013 Mar 14.
Abstract
Small interfering RNA (siRNA) therapeutics have advanced from bench to clinical trials in recent years, along with new tools developed to enable detection of siRNA delivered at the organ, cell, and subcellular levels. Preclinical models of siRNA delivery have benefitted from methodologies such as stem-loop quantitative polymerase chain reaction, histological in situ immunofluorescent staining, endosomal escape assay, and RNA-induced silencing complex loading assay. These technologies have accelerated the detection and optimization of siRNA platforms to overcome the challenges associated with delivering therapeutic oligonucleotides to the cytosol of specific target cells. This review focuses on the methodologies and their application in the biodistribution of siRNA delivered by lipid nanoparticles.
摘要
近年来，小干扰 RNA (siRNA) 治疗药物已经从实验室走向临床试验，同时也开发了新的工具来实现对器官、细胞和亚细胞水平递送到的 siRNA 的检测。siRNA 递送的临床前模型受益于一些方法，如茎环定量聚合酶链反应、组织原位免疫荧光染色、内体逃逸测定和 RNA 诱导沉默复合物加载测定。这些技术加速了 siRNA 平台的检测和优化，以克服将治疗性寡核苷酸递送到特定靶细胞胞质溶胶的相关挑战。本综述重点介绍了这些方法及其在脂质纳米颗粒递送到的 siRNA 生物分布中的应用。
相似文献
1
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.用于研究脂质纳米颗粒-siRNA 递送达有效率的生理障碍的技术。
J Histochem Cytochem. 2013 Jun;61(6):407-20. doi: 10.1369/0022155413484152. Epub 2013 Mar 14.
2
Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.通过脂质纳米颗粒平台对小干扰RNA肝脏递送的生理和生化屏障进行定量分析。
Mol Pharm. 2014 May 5;11(5):1424-34. doi: 10.1021/mp400584h. Epub 2014 Apr 1.
3
Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.了解 pH 敏感阳离子脂质的构效关系有助于合理鉴定有前途的用于体内递送 siRNA 的脂质纳米粒。
J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2.
4
Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery.脂质纳米粒介导给药后小干扰 RNA 在器官和细胞水平的分布。
J Histochem Cytochem. 2011 Aug;59(8):727-40. doi: 10.1369/0022155411410885.
5
Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.带负电荷的 siRNA 的中和作用导致负载高水平 siRNA 的脂质纳米颗粒具有更好的安全性和高效的基因沉默活性。
J Control Release. 2018 Aug 28;284:179-187. doi: 10.1016/j.jconrel.2018.06.017. Epub 2018 Jun 21.
6
Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.用于癌症治疗中 siRNA 递送的基于脂质的纳米颗粒：范例与挑战。
Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p. Epub 2012 May 8.
7
Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.基于脂质的小干扰RNA递送系统：漫长征程中的挑战、前景与解决方案
Curr Pharm Biotechnol. 2016;17(8):728-40. doi: 10.2174/1389201017666160401145319.
8
Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release.多功能阳离子脂质纳米颗粒促进内体逃逸和还原触发的胞质小干扰RNA释放。
Mol Pharm. 2014 Aug 4;11(8):2734-44. doi: 10.1021/mp400787s. Epub 2014 Jul 14.
9
Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.皮下给药后用于肝细胞基因沉默的 siRNA 的脂质纳米粒制剂的开发。
J Control Release. 2014 Dec 28;196:106-12. doi: 10.1016/j.jconrel.2014.09.025. Epub 2014 Oct 5.
10
Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.用于 siRNA 递送的多功能 pH 敏感氨基脂质
Bioconjug Chem. 2016 Jan 20;27(1):19-35. doi: 10.1021/acs.bioconjchem.5b00538. Epub 2015 Dec 17.
引用本文的文献
1
GL67 lipid-based liposomal formulation for efficient siRNA delivery into human lung cancer cells.用于将小干扰RNA高效递送至人肺癌细胞的GL67脂质体剂型
Saudi Pharm J. 2023 Jul;31(7):1139-1148. doi: 10.1016/j.jsps.2023.05.017. Epub 2023 May 19.
2
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics.监管指南和临床前工具研究 RNA 治疗药物的生物分布。
Adv Drug Deliv Rev. 2022 May;184:114236. doi: 10.1016/j.addr.2022.114236. Epub 2022 Mar 26.
3
Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation.气管内给予小干扰RNA可引发肺内信使核糖核酸沉默，从而调节T细胞免疫反应和肺部炎症。
Mol Ther Nucleic Acids. 2019 Jun 7;16:194-205. doi: 10.1016/j.omtn.2019.02.013. Epub 2019 Feb 26.
4
Injectable, Guest-Host Assembled Polyethylenimine Hydrogel for siRNA Delivery.用于小干扰RNA递送的可注射、客体-主体组装聚乙烯亚胺水凝胶
Biomacromolecules. 2017 Jan 9;18(1):77-86. doi: 10.1021/acs.biomac.6b01378. Epub 2016 Dec 20.
5
Cellular Delivery of RNA Nanoparticles.RNA纳米颗粒的细胞递送
ACS Comb Sci. 2016 Sep 12;18(9):527-47. doi: 10.1021/acscombsci.6b00073. Epub 2016 Aug 26.
6
Three-dimensional localization of polymer nanoparticles in cells using ToF-SIMS.使用飞行时间二次离子质谱法对细胞内聚合物纳米颗粒进行三维定位
Biointerphases. 2015 Jun 3;11(2):02A304. doi: 10.1116/1.4934795.
7
Current progress on aptamer-targeted oligonucleotide therapeutics.适体靶向寡核苷酸疗法的当前进展。
Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118.
本文引用的文献
1
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.系统性 RNAi 介导的非人类灵长类动物和啮齿类动物髓样细胞中的基因沉默。
Mol Ther Nucleic Acids. 2012 Jan 24;1(1):e4. doi: 10.1038/mtna.2011.3.
2
Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.经涂覆钢微针递送至皮肤的 siRNA 后的基因沉默：体内和体外概念验证。
J Control Release. 2013 Mar 28;166(3):211-9. doi: 10.1016/j.jconrel.2012.12.030. Epub 2013 Jan 8.
3
Intravital fluorescence imaging of small interfering RNA-mediated gene repression in a dual reporter melanoma xenograft model.活体荧光成像检测双报告基因黑素瘤异种移植模型中小干扰 RNA 介导的基因沉默。
Nucleic Acid Ther. 2012 Dec;22(6):438-43. doi: 10.1089/nat.2012.0364. Epub 2012 Oct 25.
4
Translational siRNA therapeutics using liposomal carriers: prospects & challenges.利用脂质体载体的 siRNA 治疗药物：前景与挑战。
Curr Gene Ther. 2012 Aug;12(4):315-32. doi: 10.2174/156652312802083611.
5
Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects.用于癌症治疗的小干扰RNA的递送与生物分布：挑战与未来前景
Ther Deliv. 2012 Feb;3(2):245-61. doi: 10.4155/tde.11.155.
6
RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.RNA 干扰触发变体：最大限度地利用 RNA 进行基于 RNA 干扰的治疗。
Nucleic Acid Ther. 2012 Jun;22(3):139-46. doi: 10.1089/nat.2012.0361.
7
RNA-based therapeutics: current progress and future prospects.基于RNA的疗法：当前进展与未来前景
Chem Biol. 2012 Jan 27;19(1):60-71. doi: 10.1016/j.chembiol.2011.12.008.
8
Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics.脂质型短干扰核糖核酸治疗药物的药物研发挑战。
Expert Opin Drug Deliv. 2012 Feb;9(2):171-82. doi: 10.1517/17425247.2012.642363.
9
Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.利用对流增强递送 siRNA 广泛抑制亨廷顿病。
Exp Neurol. 2012 Jan;233(1):463-71. doi: 10.1016/j.expneurol.2011.11.020. Epub 2011 Nov 19.
10
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.PCSK9 LNA 反义寡核苷酸可诱导非人灵长类动物 LDL 胆固醇持续降低。
Mol Ther. 2012 Feb;20(2):376-81. doi: 10.1038/mt.2011.260. Epub 2011 Nov 22.
Zotero 插件